Associated Papers
Impact of SARS-CoV-2 variant mutations on susceptibility to monoclonal antibodies and antiviral drugs: a non-systematic review, April 2022 to October 2024.
Vukovikj M et al.
Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin, 2025
40084420 (PubMed )
Supplement: 24-00252_BROBERG_Supplement.pdf
SARS-CoV-2 journey: from alpha variant to omicron and its sub-variants.
Hattab D et al.
Infection, 2024
Diverse array of neutralizing antibodies elicited upon Spike Ferritin Nanoparticle vaccination in rhesus macaques.
Sankhala RS et al.
Nature Communications, 2024
Neutralization, effector function and immune imprinting of Omicron variants.
Addetia A et al.
Nature, 2023
Viral Instant Mutation Viewer: A Tool to Speed Up the Identification and Analysis of New SARS-CoV-2 Emerging Variants and Beyond.
Wilde V et al.
Viruses, 2023
Therapeutic and vaccine-induced cross-reactive antibodies with effector function against emerging Omicron variants.
Addetia A et al.
Biorxiv : the Preprint Server for Biology, 2023
Genomic Analysis of Non-B Nucleic Acids Structures in SARS-CoV-2: Potential Key Roles for These Structures in Mutability, Translation, and Replication?
Bidula S et al.
Genes, 2023
First cases of infection with the 21L/BA.2 Omicron variant in Marseille, France.
Colson P et al.
Journal of Medical Virology, 2022
Select a paper to view details